7.7.7. treatment patients bone metastases. prevalence metastatic bone disease (mbd) patients advanced/metastatic uc 30–40% . interestingly, recent report described several observations related age- sex-related differences distribution metastases patients metastatic bc demonstrated bone common metastatic site men differences noted according patient age sex . skeletal complications due mbd detrimental effect pain qol also associated increased mortality . bisphosphonates zoledronic acid reduce delay skeletal-related events (sres) due bone metastases inhibiting bone resorption, shown small pilot study . denosumab, fully human monoclonal antibody binds neutralises rankl (receptor activator nuclear factor κb ligand), shown non-inferior zoledronic acid preventing delaying sres patients solid tumours advanced mbd, including patients uc . patients mbd, irrespective cancer type, considered bone-targeted treatment . patients treated zoledronic acid denosumab informed possible side effects including osteonecrosis jaw hypocalcaemia. supplementation calcium vitamin mandatory. dosing regimens zoledronic acid follow regulatory recommendations adjusted according pre-existing medical conditions, especially renal function . denosumab, dose adjustments required variations renal function.